At the core of this innovation lies the intricate process of RNA splicing—a fundamental biological mechanism where precursor messenger RNA (pre-mRNA) transcripts undergo selective removal of non-coding introns and the joining of coding exons. Alternative splicing expands the proteomic repertoire of cells, enabling a single gene to produce multiple protein isoforms. However, dysregulation of this mechanism is implicated in various human diseases, including cancers, neurodegenerative conditions, and inherited genetic disorders. Thus, the capacity to externally modulate RNA splicing opens up transformative potential for correcting aberrant gene expression profiles.

The team, led by Mendel, Schwarz, and Sun, has shown that a small molecule, already in clinical use for unrelated indications, can be repurposed to manipulate splicing outcomes by binding to specific components of the spliceosome complex, the cellular machinery responsible for RNA splicing. This binding event shifts the splicing equilibrium, promoting the inclusion or exclusion of targeted exons, effectively turning gene expression ‘up’ or ‘down’ with remarkable precision. Unlike gene editing techniques which rely on altering the DNA code itself, this RNA-centric approach allows reversible, adjustable, and more nuanced gene control without permanent genomic changes.

One of the remarkable facets of this discovery is the tunability of gene expression control. The researchers demonstrated that varying the concentration and exposure duration of the small molecule enabled graded responses in splicing patterns, translating to dose-dependent changes in protein production. This tunability was confirmed across multiple gene targets and cell types, suggesting broad applicability. Moreover, because the compound in question is already clinically approved, it carries an established safety profile, potentially accelerating the transition from bench to bedside.

Mechanistically, the small molecule’s binding alters the conformational dynamics of spliceosomal proteins involved in recognizing and processing splicing sites. By stabilizing or destabilizing certain spliceosome intermediates, the molecule effectively ‘redirects’ the splicing machinery towards alternative splice site usage. Detailed biochemical assays and structural studies corroborated these findings, elucidating the molecular interactions at play and paving the way for rational design of next-generation splicing modulators with enhanced specificity.

Beyond the fundamental science, the therapeutic implications of this technology are vast. Genetic diseases caused by splicing defects, such as spinal muscular atrophy or certain forms of cystic fibrosis, stand to benefit immensely from a modality that can restore normal splicing patterns. Additionally, cancers driven by aberrant splicing isoforms could be sensitized to treatment by selectively switching splice variants. The reversible nature of this control also mitigates risks associated with permanent genetic modifications, offering a safer therapeutic window.

Further experiments using patient-derived cells demonstrated functional rescue of disease phenotypes following treatment with the small molecule. Correction of faulty splicing resulted in restoration of normal protein function and amelioration of cellular deficits associated with disease. These results not only validate the clinical promise but also highlight the adaptability of the approach for personalized medicine where gene expression patterns need tailored modulation.

Importantly, the study also delved into potential off-target effects and long-term safety. Comprehensive transcriptomic analyses revealed a high degree of specificity, with minimal unintended splicing changes beyond the intended gene targets. Chronic exposure studies indicated that cells maintain viability and normal function, alleviating concerns of toxicity. Nonetheless, the researchers emphasize that ongoing vigilance and refinement will be essential as this technology advances towards clinical trials.

From a broader perspective, this work represents a conceptual leap in the field of synthetic biology and gene regulation. It integrates deep molecular understanding with practical therapeutic insights, demonstrating how modulating RNA processing pathways can serve as a powerful lever to control gene function dynamically. This opens exciting possibilities for developing small molecule libraries capable of targeting diverse splicing events to manipulate cellular phenotypes at will.

The collaboration across disciplines—combining structural biology, chemical pharmacology, genomics, and clinical expertise—was critical to achieving this milestone. Cutting-edge experimental platforms such as cryo-electron microscopy and high-throughput RNA sequencing played pivotal roles in deciphering the mechanism and breadth of splicing control. This multidisciplinary blueprint sets a new standard for how complex molecular therapies can be developed efficiently and rationally.

Looking ahead, the research team envisions expanding this platform to include combinatorial control of multiple splicing events simultaneously, enabling sophisticated gene expression programming akin to biological circuits. Such capabilities could revolutionize regenerative medicine, oncology, and even neurotherapeutics by allowing environment-responsive or temporally gated interventions.

In addition to therapeutic applications, the insights gained from this study deepen our fundamental understanding of spliceosome plasticity and its regulation by small molecules. This knowledge could inspire targeted chemical biology tools aimed at mapping intricate RNA networks and decoding disease-associated splicing alterations at unprecedented resolution.

As this innovative approach matures, the convergence of safe, tunable splicing modulators with precision medicine infrastructure holds promise for transforming how we diagnose, treat, and potentially cure myriad genetic conditions. By harnessing the power of RNA, a more flexible and accessible layer of gene regulation emerges, heralding a new era in molecular therapeutics.

In summary, the discovery that a clinically approved small molecule can be repurposed to exert tunable control over gene expression by modulating RNA splicing represents a landmark breakthrough. It provides a versatile, precise, and safe platform to manipulate cellular function with direct clinical relevance. The implications extend from fundamental biology to personalized therapies, offering hope for addressing previously intractable genetic diseases with elegance and efficiency.

Subject of Research: Gene regulation through RNA splicing modulation using a clinically approved small molecule.

Article Title: Tunable gene control via RNA splicing with a clinically approved small molecule.

Article References:
Mendel, M., Schwarz, D., Sun, T. et al. Tunable gene control via RNA splicing with a clinically approved small molecule. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73673-1

Image Credits: AI Generated

In the intricate cellular environment, DNA serves as the master blueprint encoding the instructions for life. However, it is not the DNA itself that directly orchestrates cellular functions but rather RNA molecules copied from DNA that act as the functional intermediaries. These RNA transcripts translate genetic codes into proteins and regulate critical biological processes. The fidelity of these RNA copies, however, is a double-edged sword; errors during transcription or dysregulated RNA activity can contribute to pathological states such as cancer, where aberrant signals drive uncontrolled cell proliferation.

Traditional CRISPR-based technologies have largely centered on DNA targets, making permanent genomic alterations. More recently, innovations have allowed targeting RNA, providing a means to modulate gene expression dynamically without altering the genome’s foundational instructions. Yet, existing RNA-targeting CRISPR systems rely on RNA guides to locate their targets. These RNA guides, while effective, suffer from instability, propensity for degradation, and significant off-target effects, limiting their clinical utility and increasing costs.

The University of Florida’s novel approach overturns this limitation by employing DNA molecules as guides for the CRISPR-Cas12 enzyme, diverging fundamentally from prior methodologies. DNA guides offer superior stability and manufacturability compared to their RNA counterparts, mitigating degradation issues and markedly reducing the incidence of unintended molecular interactions. This refined targeting contributes to a dramatic leap in specificity, empowering researchers to zero in on problematic RNA molecules with unprecedented accuracy.

By focusing on RNA targets using DNA guides, scientists have devised a system capable of fine-tuning cellular instructions in real time without altering the genome’s permanent code. This capability enables therapeutic interventions at a level of control hitherto unattainable—interrupting pathological signals and rectifying RNA-related anomalies before committing to irreversible DNA edits. Such an approach could significantly improve patient safety by allowing initial, reversible modulation of disease processes.

Beyond the enhanced precision, DNA guidance translates into tangible economic benefits. DNA molecules are inherently more stable and easier to synthesize at scale than RNA, substantially lowering production costs for CRISPR components. The cost-effectiveness and robustness of such reagents promise to democratize access to advanced gene-editing tools, broadening their application from cutting-edge research labs to clinical settings, particularly in resource-constrained environments.

Another transformative implication of this technology is its diagnostic potential. The new DNA-guided system has demonstrated remarkable sensitivity and accuracy in detecting viral pathogens. It can identify viruses such as HIV in their earliest stages and detect hepatitis C with perfect accuracy, reinforcing its promise as a frontline diagnostic tool. Early and precise pathogen detection could revolutionize infectious disease management, enabling rapid responses and improving outcomes.

The research team, led by Dr. Piyush Jain, emphasizes that this achievement was not without significant challenges. The project demanded innovative thinking and persistence, challenging the entrenched dogma that RNA must serve as the guiding molecule in CRISPR systems targeting RNA. Doctoral candidates and postdoctoral researchers Carlos Orosco, Boyu Huang, and Santosh Rananaware played essential roles in bringing this vision to reality, illustrating the power of questioning established scientific norms.

Looking forward, the research opens exciting avenues for a broad spectrum of applications. From developing highly targeted therapies to crafting enhanced diagnostic platforms, the possibilities extend to investigating the molecular underpinnings of diseases with newfound clarity. The ability to modulate RNA activity precisely could unlock fresh insights into cellular dynamics and disease progression, fueling novel therapeutic strategies.

In tandem, the team is exploring the use of this technology in organ transplantation. Gene-editing tools guided by DNA may offer opportunities to repair and optimize donor organs ex vivo before transplantation, potentially improving graft survival and patient outcomes. Such applications underscore the versatility and transformative nature of DNA-guided CRISPR systems across biomedical disciplines.

Despite the immense promise, DNA-guided CRISPR remains in early-stage development. Regulatory pathways and rigorous clinical testing will be essential before widespread therapeutic deployment. Yet, the recognition by federal agencies, including the National Institutes of Health, the Food and Drug Administration, and the Advanced Research Projects Agency for Health, signals strong governmental support for accelerating the translation of RNA-targeting gene-editing technologies into clinical practice.

Dr. Jain envisions initial clinical applications to emerge within a few years, especially in settings where cells or tissues are treated outside the human body—such as in cell therapies or organ culture systems. These ex vivo interventions provide controlled environments for testing the safety and efficacy of DNA-guided CRISPR, paving the way for eventual in vivo uses that may transform patient care paradigms across various genetic and infectious diseases.

This milestone not only redefines technical capabilities but also enriches the conceptual framework of CRISPR biology. For decades, RNA guides were considered indispensable for directing CRISPR enzymes to RNA targets. By demonstrating that DNA can fulfill this role with distinct advantages, the University of Florida team has expanded the genetic toolkit and challenged the scientific community to rethink the mechanisms and possibilities of gene editing.

Ultimately, the DNA-guided CRISPR system heralds a new chapter of enhanced control over genetic regulation—beyond merely rewriting DNA, it enables nuanced management of the molecular instructions as they are executed within cells. This advance could serve as a cornerstone for future innovations that couple deep biological insight with therapeutic precision, driving forward the frontier of molecular medicine.

Subject of Research: DNA-guided CRISPR system for precise RNA targeting in cells
Article Title: DNA-guided CRISPR–Cas12 for cellular RNA targeting
News Publication Date: 15-May-2026
Web References:

• 2024 preprint: https://www.medrxiv.org/content/10.1101/2024.11.21.24317744v1
• Nature Biotechnology article: https://www.nature.com/articles/s41587-026-03129-w
  References: DOI: 10.1038/s41587-026-03129-w
  Keywords: CRISPR, DNA-guided CRISPR, RNA targeting, gene editing, molecular diagnostics, RNA modulation, gene therapy, viral detection, hepatitis C, HIV detection, precision medicine, gene regulation

Professor Claudia Höbartner of the University of Würzburg has emerged as a pioneering figure in this nascent field, significantly advancing our comprehension of catalytic nucleic acids through her rigorous structural and functional investigations. Holding the Chair of Organic Chemistry I at Würzburg, she is instrumental in spearheading research activities within the Würzburg-Munich Cluster of Excellence NUCLEATE, a multidisciplinary initiative aimed at elucidating nucleic acid catalysis and harnessing its potential in synthetic biology and molecular medicine. Her work integrates cutting-edge techniques in structural biology, chemical synthesis, and molecular biophysics to decode the complexities of nucleic acid catalysis, challenging the traditional protein-centric view of enzymology.

In recognition of her groundbreaking contributions, the German Chemical Society (GDCh) bestowed upon Professor Höbartner the prestigious Albrecht Kossel Prize during the 2026 GDCh Biochemistry conference held in Würzburg. This accolade, named after the Nobel laureate Ludwig Kossel who made seminal discoveries in nucleic acid chemistry, underscores the high esteem in which her discoveries are held within the international scientific community. The award ceremony was marked by laudatory addresses from GDCh President Ruth Bieringer and Professor Andrea Rentmeister of LMU Munich, both emphasizing Professor Höbartner’s scientific passion and transformative insights.

A hallmark of Höbartner’s work includes the world-first determination of the three-dimensional structure of a DNAzyme—a DNA molecule with catalytic activity—an achievement that elucidates the molecular underpinnings of its catalytic mechanism. Prior to this, structural information about DNAzymes had remained elusive, limiting the ability to rationally design and optimize such biomolecules for applications. Her elucidation of DNAzyme structure has not only provided vital clues into how nucleic acids can orchestrate complex chemical reactions but has also paved the way for leveraging these molecules in nanotechnology, biosensing, and therapeutic contexts.

Equally momentous is her discovery of a ribozyme capable of transferring methyl groups, a biochemical function previously attributed predominantly to protein enzymes. Methyl group transfer is a critical epigenetic modification influencing gene expression, and uncovering a ribozyme with this capability suggests profound evolutionary and biomedical implications. Her findings imply that catalytic RNAs could have played a pivotal role in primordial biochemical pathways, supporting theories on the RNA world hypothesis that posit RNA as both genetic material and catalyst in early life forms. This discovery also opens innovative avenues in synthetic biology, where RNA-based catalysts may be engineered to introduce site-specific modifications or regulate molecular processes.

The research outputs of Professor Höbartner have gained global recognition through their publication in Nature, one of the most authoritative journals in science, thereby setting a new standard in nucleic acid catalysis research. Her studies intricately combine high-resolution structural analysis with biochemical assays, advancing the understanding of nucleotide modifications and catalytic dynamics. This holistic approach enables a richer portrayal of nucleic acid enzymology and fosters the translation of fundamental science into practical technologies.

Tracing her academic trajectory, Claudia Höbartner’s career is marked by international collaborations and prestigious appointments. After earning her degree in Technical Chemistry from the Vienna University of Technology in 2001 and her PhD in Chemistry from the University of Innsbruck in 2004, she expanded her expertise through postdoctoral research at the University of Illinois at Urbana-Champaign—a global leader in molecular biology—and subsequently returned to Innsbruck. Her postdoctoral work facilitated her proficiency in both chemical synthesis and molecular biophysics, critical for her future explorations of nucleic acid enzymes.

From 2008 onwards, she led a research group at the Max Planck Institute for Biophysical Chemistry in Göttingen, a hub renowned for advancements in physical and molecular biosciences. In 2014, she assumed a professorship in Göttingen, before transitioning in 2017 to her current position at Julius-Maximilians-Universität Würzburg. Throughout her career, Höbartner has continued to bridge chemical innovation with biological inquiry, reinforcing Würzburg’s status as a center of excellence in organic and biological chemistry.

Her stellar scientific accomplishments have earned her election in 2022 to the German National Academy of Sciences Leopoldina, an honor that reflects her pivotal role in shaping modern chemical biology. Further accolades followed, including the 2023 Gottfried Wilhelm Leibniz Prize, which is Germany’s highest research honor, and the Bavarian Order of Merit, recognizing her contributions both as a scholar and an ambassador of science. Since 2023, Höbartner has also been a vital member of the Executive Committee of the GDCh Biochemistry Division, lending her expertise to guide the future direction of biochemical research in Germany.

The Albrecht Kossel Prize, first awarded in 2014, is a distinguished recognition bestowed by the GDCh to honor significant advances in nucleic acid chemistry, commemorating Ludwig Kossel’s foundational work on the cell nucleus and nucleic acid composition. This prize not only celebrates scientific achievement but also highlights the enduring relevance of nucleic acid research in contemporary science and medicine. The German Chemical Society itself, boasting approximately 28,000 members across diverse specializations, fosters scholarly exchange and innovation, nurturing talents like Professor Höbartner who pioneer interdisciplinary frontiers.

Professor Claudia Höbartner’s exemplary work underscores the transformative potential of catalytic nucleic acids in redefining enzymology and molecular function. Her research offers a glimpse into ancient biochemical phenomena while simultaneously forging new pathways for medical and technological innovation. As catalysis by nucleic acids unfolds as a versatile and powerful paradigm, her discoveries continue to inspire scientists worldwide, heralding an era where DNA and RNA are not only information carriers but dynamic architects of molecular complexity.

Subject of Research: Catalytic nucleic acids, RNA and DNAzymes, nucleic acid structure and function, enzymatic methylation, origins of life chemistry, synthetic biology.

Article Title: Celebrating Claudia Höbartner: Unveiling the Catalytic Power of Nucleic Acids

News Publication Date: March 17, 2026

Web References:
https://www.uni-wuerzburg.de/en/nucleate/

References:
Publications in Nature detailing DNAzyme structure and methyltransferase ribozyme discoveries by Claudia Höbartner.

Image Credits:
Alexander Draheim / Gesellschaft Deutscher Chemiker

Keywords

Catalytic nucleic acids, DNAzyme, ribozyme, methyltransferase activity, nucleic acid structure, enzymology, origins of life, synthetic biology, Claudia Höbartner, Albrecht Kossel Prize, nucleic acid catalysis, GDCh.

Oligonucleotides (ONs), short synthetic strands of nucleotides—the fundamental units of DNA and RNA—are rapidly emerging as groundbreaking agents in molecular medicine. Unlike conventional drugs that often target downstream symptoms, ONs intervene at the genetic level by delivering precise molecular instructions that modulate gene expression. By selectively binding to RNA, these molecules can inhibit the production of deleterious proteins directly responsible for pathological conditions such as cancer and chronic inflammatory diseases, thus halting disease progression at its root.

Despite their revolutionary potential, oligonucleotide therapies face critical challenges that hinder their widespread clinical adoption. Chief among these are their inherent instability within biological systems, making them susceptible to rapid degradation by nucleases in the bloodstream. Additionally, achieving effective and targeted delivery to the appropriate cell types remains difficult due to physiological barriers. Compounding these issues, off-target effects and immune system activation sometimes cause adverse reactions. The new ON-TRACT project is laser-focused on overcoming these hurdles by developing novel stabilization methods, optimized delivery vehicles, and safety-enhancing formulations.

The ON-TRACT consortium’s multi-disciplinary approach leverages expertise from synthetic chemistry, chemical engineering, molecular biology, and clinical sciences to develop robust oligonucleotide platforms capable of precise targeting and sustained activity. Advanced chemical modifications of the oligonucleotide backbone and sugar-phosphate moieties are being engineered to enhance nuclease resistance while preserving or improving hybridization affinity for target RNA sequences. These semi-synthetic nucleic acid analogues aim to prolong therapeutic half-life and reduce immunogenicity.

Efficient intracellular delivery is another cornerstone of the ON-TRACT research agenda. The project explores innovative carriers such as lipid nanoparticles, conjugated peptides, and polymer-based nanoparticles that can navigate the complex cellular microenvironment. These vectors are designed to facilitate the endosomal escape of ONs, ensuring their bioavailability within the cytoplasm or nucleus where gene regulation occurs. Researchers are carefully tuning the physicochemical properties of these carriers to optimize biodistribution and minimize off-target interactions or toxicity.

A particularly transformative dimension of ON-TRACT is its commitment to sustainability and ethical experimentation. Rather than relying on animal models, the project adopts cutting-edge organoid technology, cultivating three-dimensional mini-organs from patient-derived stem cells. These organoids faithfully recapitulate human tissue architecture and function, enabling high fidelity preclinical assessment of oligonucleotide efficacy and safety. This paradigm not only accelerates translational research but also aligns with evolving regulatory and ethical standards prioritizing reduction of animal use.

Training the next generation of life science innovators is integral to the ON-TRACT endeavour. Fourteen doctoral candidates distributed across academic, industrial, and clinical partner institutions in multiple European countries—including the UK, Sweden, France, Poland, Belgium, and Italy—will receive rigorous interdisciplinary education. Their research projects will span fundamental nucleic acid chemistry, formulation science, delivery system engineering, and translational oncology, preparing them to be leaders in the burgeoning fields of nucleic acid therapeutics and precision medicine.

The therapeutic focus of ON-TRACT spans several critical diseases with high unmet medical need, including lung cancer, hematological malignancies such as blood cancers, and chronic inflammatory conditions. These complex diseases often elude existing drug modalities due to genetic heterogeneity and dynamic pathological mechanisms. By harnessing the molecular specificity of oligonucleotides, the project aims to tailor treatments that are not only highly effective but also minimize systemic toxicity, heralding a new era of personalized medicine.

The University of Southampton spearheads this effort, collaborating closely with distinguished partners such as the University of Cambridge, Karolinska Institute, AstraZeneca, Centre Nationale de la Recherche CNRS, and others, reflecting a robust European research network. Together, the consortium pools diverse expertise and cutting-edge technologies to push oligonucleotide science from the bench to bedside, addressing major challenges that have so far limited clinical impact.

This initiative complements Southampton’s involvement in the INT2ACT consortium, which focuses on nucleic acids (NAs) broadly as diagnostic and therapeutic tools. While INT2ACT advances nucleic acid applications across multiple disease spectra, ON-TRACT zeroes in on refining oligonucleotide stability, delivery, and safety specifically for cancer and chronic inflammation. This symbiotic relationship between projects amplifies scientific progress and accelerates pipeline development for nucleic-acid-based medicines.

The future envisioned by ON-TRACT could radically alter current paradigms in oncology and immunomodulation, providing patients with targeted treatments capable of rewiring their genetic circuitry. As oligonucleotide therapies gain traction, the promise of durable remissions, fewer side effects, and tailored therapeutic regimens becomes increasingly attainable. These advances are poised to reshape healthcare by aligning molecular precision with patient-specific biology.

In addition to their therapeutic promise, oligonucleotide technologies hold wider implications for sustainable pharmaceutical manufacturing. ON-TRACT explores greener synthesis methods to reduce environmental impact, including enzymatic synthesis and minimization of hazardous reagents. This sustainability focus aligns with global trends for eco-friendly drug production and responsible innovation, ensuring that progress benefits both health and planetary wellbeing.

In summary, the ON-TRACT project represents a bold and comprehensive effort to overcome longstanding barriers in oligonucleotide therapeutics. By integrating cutting-edge chemistry, advanced delivery science, ethical model systems, and extensive training initiatives, the consortium is laying the groundwork for transformative treatments for cancer and chronic inflammatory diseases. With its multisectoral European collaboration and visionary scientific agenda, ON-TRACT is positioned to accelerate the arrival of next-generation precision medicines that target the genetic origins of disease with unprecedented accuracy and safety.

Subject of Research: Development of next-generation oligonucleotide-based therapies for cancer and chronic inflammation, focusing on enhancing stability, delivery, and safety.

Article Title: Revolutionizing Cancer and Inflammation Treatment: The ON-TRACT Oligonucleotide Initiative

News Publication Date: Not specified

Web References:

• University of Southampton
• INT2ACT MSCA Programme

Keywords: Cancer, Oncology, Cancer genomics, Inflammation, Blood cancer